Circulating Isovalerylcarnitine and Lung Cancer Risk: Evidence from Mendelian Randomization and Prediagnostic Blood Measurements

Karl Smith-Byrne(University of Oxford), J. Brent Richards(McGill University Health Centre), David Schibli(University of Victoria), Torkjel M. Sandanger(UiT The Arctic University of Norway), Liher Imaz(Basque Government), Krasimira Aleksandrova(Leibniz Institute for Prevention Research and Epidemiology - BIPS), María‐Dolores Chirlaque(Hospital Universitari Sant Joan de Reus), Florence Guida(Centre international de recherche sur le cancer), Antonio Agudo(Institut Català d'Oncologia), Christopher I. Amos(The University of Texas MD Anderson Cancer Center), Ruth C. Travis(University of Oxford), Tilman Kühn(Queen's University Belfast), Jun Han(University of Victoria), Rudolf Kaaks(German Cancer Research Center), Mattias Johansson(Centre international de recherche sur le cancer), Matthias B. Schulze(Brigham and Women's Hospital), Rayjean J. Hung, Inger Torhild Gram(St. Elizabeth's Hospital), Sirui Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Hilary A. Robbins(Centre international de recherche sur le cancer), Aurelio Barricarte(Instituto de Salud Pública de Navarra), Richard M. Martin(Drug Safety Research Unit), Kjell Grankvist(Umeå University), Miguel Rodríguez‐Barranco, Agustin Cerani(Jewish General Hospital), Elisabete Weiderpass(Centre international de recherche sur le cancer), Paolo Vineis(Imperial College London), James McKay(Centre international de recherche sur le cancer), Mikael Johansson(Centre international de recherche sur le cancer), Therese Haugdhal Nøst(UiT The Arctic University of Norway), Paul Brennan(Centre international de recherche sur le cancer), Christoph H. Bochers(University of Victoria), Valeria Pala
Cancer Epidemiology Biomarkers & Prevention
July 15, 2022
Cited by 14


Related Papers